Navigation Links
Sorrento Therapeutics to Present at Two Healthcare Conferences
Date:9/6/2013

tellectual property rights of others; the potential that Sorrento may require substantial additional funding in order to obtain regulatory approval for and commercialize Sorrento Therapeutics' proprietary G-MAB® fully-human antibody library platform technologies or product candidates; and additional risks set forth in Sorrento Therapeutics' filings with the Securities and Exchange Commission. These forward-looking statements represent Sorrento Therapeutics' judgment as of the date of this release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and STI undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
2. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
3. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
4. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
5. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
6. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
7. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
8. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
9. Sorrento Therapeutics Awarded Third Phase I STTR Grant
10. Mast Therapeutics Hosting 2nd Annual Sickle Cell Disease Therapeutics Conference On September 19, 2013
11. Signature Therapeutics, Inc., Presents Four Scientific Posters Today at PAINWeek 2013 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... VIENNA , Sept. 19, 2014 ... positive interim clinical data for its lead candidate ITCA ... diabetes patients with high baseline HbA1c levels at the ... for the Study of Diabetes (EASD). Data from the ... reduced levels of blood sugar in patients with poorly ...
(Date:9/19/2014)... and CAMBRIDGE, Mass. ... Inc. (PGDx), a provider of advanced cancer ... Medicines , a leader in discovering and developing ... today disclosed the first-ever comprehensive genomic study of ... deadly cancer of the female reproductive system, also ...
(Date:9/19/2014)... Sept. 19, 2014  PCI is pleased to ... Biotec is a leading provider of Clinical Trial ... Bridgend, Wales in the ... significantly expands PCI,s presence in the UK/EU to ... adding packaging, storage and distribution capacity, as well ...
Breaking Medicine Technology:Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6
(Date:9/21/2014)... 21, 2014 Originally approved by ... GSK’s Flovent (fluticasone propionate) is a synthetic ICS ... for the maintenance treatment of asthma prophylactically in ... two formulations, Diskus and HFA, which received the ... active ingredient, fluticasone propionate, can bind to glucocorticoid ...
(Date:9/21/2014)... 2014 To accommodate the ever-growing customer ... provide more trendy items. Recently, the company has unveiled ... the new and elegant wedding gowns, Angeldress.co.uk wants to ... need in an easy way. Its high quality vintage ... from 12% off to 62% off. , Online shopping ...
(Date:9/21/2014)... New York, NY (PRWEB) September 21, 2014 ... ( http://www.thegranuflolawsuit.com/ ) have been added over the ... involving claims that allege serious cardiovascular injuries caused ... , A Case List updated on September 15th ... underway in the U.S. District Court, District of ...
(Date:9/21/2014)... “Cluster headaches are sometimes called ‘Suicide Headaches’ because ... said Steve Young of Ew Publishing; “I’ve had cluster ... is more intense.” , “It should be a relief ... that medical research is pointing to some relief and ... Serotonin (5-HT, 5-hydroxytryptamine) is a ubiquitous biochemical found in ...
(Date:9/21/2014)... Developers and plugin specialist of Final ... transition plugin entitled Transpack Vol. 3 from Pixel Film ... that will add a level of professionalism to any ... Film Studios. “Blurring the line between professional and armature, ... Transpack Vol. 3 returns with over 85 all new ...
Breaking Medicine News(10 mins):Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Angeldress.co.uk Launches New Range Of 2014 Vintage Wedding Dresses In Its Online Store 2Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 2Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 3Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 4Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2Health News:Pixel Film Studios Released Transpack Vol. 3 Plugin Exclusively for Final Cut Pro X 2
... benefit from liver supportive liver therapy while ... to enable bridging to liver transplantation. Albumin ... and renal function as well as the ... hemodynamic alterations in stable patients with cirrhosis ...
... Digestive Disease Week (DDW), SAN DIEGO, May ... Disease Week meeting that showed Cimzia(R) (certolizumab pegol),provided ... than 60 percent,of Crohn,s disease patients who were ... percent of patients achieved remission by six weeks.,Data ...
... Depression is a serious,but treatable health condition that ... be the focus of a national campaign during Mental,Health ... is,supported by the Anthem Blue Cross Foundation, the charitable ... Depression National Awareness Campaign is an effort to,increase knowledge, ...
... to introduce local physicians to new facility, SAN CARLOS, ... of its newest facility in San Carlos, welcoming doctors,located within ... was on hand to mingle with guests and provide tours ... were in attendance to learn about,SleepQuest,s services and the benefits ...
... Ltd. (Amex: CPD ) announced that the ... fiscal year 2008 ended March 31, 2008,prior to ... Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops,manufactures, markets ... largest wholesalers, distributors,drugstore chains and managed care providers., ...
... find tissue that normally lines the stomach in locations outside ... identified in such diverse locations as the scrotum, the gall ... a team led by Dr. Steven Paul Schmidt, is described ... of Gastroenterology. , Typically, when this gastric tissue is located ...
Cached Medicine News:Health News:Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients 2Health News:Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients 3Health News:Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients 4Health News:Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients 5Health News:Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients 6Health News:Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients 7Health News:Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients 8Health News:Anthem Blue Cross Foundation Supports National Campaign Focused on Depression Among Men 2Health News:Anthem Blue Cross Foundation Supports National Campaign Focused on Depression Among Men 3Health News:SleepQuest Holds Open House 2Health News:Caraco Pharmaceutical Laboratories, Ltd. to Announce Fourth Quarter and Fiscal Year 2008 Results on May 29, 2008 2Health News:Heterotopic gastric tissue simulating acute appendicitis 2
Liquid Assayed and Unassayed Multiqual Controls are comprehensive, liquid, human serum based chemistry controls, available in three levels....
Lyphochek Therapeutic Drug Monitoring Control (TDM) contains over 40 analytes with assayed values at three clinically significant levels....
... Urine Control contains a comprehensive ... that monitor tests for general ... hormones. It also contains hCG ... microalbumin at levels suitable for ...
qUAntify Control is designed to monitor the performance of urine dipstick testing. The control is available in 12 mL ready-to-use dropper bottles....
Medicine Products: